Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$488.3(2.3%)
Market Cap$124.8B
VRTX Rating
VRTX Quality rating performance
VRTX Intrinsic Value
Key Highlights:
As of Mar 11, 2025 VRTX Relative Value is $186.1, which is overvalued by 61.9%, compared to current share price of $488.3.
As of Mar 11, 2025 VRTX DCF Value is N/A, which is undervalued by N/A, compared to current share price of $488.3.
VRTX Share Price History
1W 0.4%
1M 7.3%
6M 2.9%
YTD 18.8%
1Y 17.8%
3Y 106.5%
5Y 121.6%
10Y 298.2%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
VRTX Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$124.8B
$120.5B
$11.0B
($790.3M)
Shares Outstanding
256M
Employees
94K
Growth (CAGR)
21.5%
N/A
Profitability
86.1%
(2.2%)
(4.9%)
(4.5%)
(7.2%)
147.6%
Intrinsic Value
$187.5 (61.6% overvalued)
N/A
$187.5
$1,688.0
(100.0%)
7.1%
Valuation (LTM)
Return on Capital
Financial Health
$6,115.9M
($4,366.4M)
5.5x
(8.1x)
10.7%
Dividends
Earnings
Jul 30, 2025
BEAT by 4.4%
MISS by (1.0%)
(5.0%)
8 Beat & 2 Miss
VRTX Stock Financials
VRTX Income Statement Metrics
Annual
Quarterly
LTM
VRTX Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($492.6M) N/A YoY
Capital Expenditure (CAPEX)
($297.7M) +15.2% YoY
Free Cash Flow (FCF)
($790.3M) N/A YoY
VRTX Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$11.0B 11.7% YoY
Cost of revenue
$1,530.5M 21.3% YoY
Operating
expenses
$9,722.5M 103.6% YoY
Other: $4,092.3M
VRTX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$22.5B
Current assets ($9,596.4M, 42.6% of total)
$6,115.9M (27.1%)
$1,609.4M (7.1%)
Other current assets
$1,871.1M (8.3%)
Non-current assets ($12.9B, 57.4% of total)
$5,107.9M (22.7%)
$2,584.6M (11.5%)
$825.9M (3.7%)
Other non-current assets
$4,418.4M (19.6%)
Financial position
($4,366.4M)
Cash & Short-term
Investments
Total Debt
VRTX Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
VRTX Earnings Surprises
Crunching data... Almost there!
VRTX Dividends
VRTX Dividend Yield
Crunching data... Almost there!
VRTX Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with VRTX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$14.2B | 5.6 | $42.2 38.1% overvalued | 12.0% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Vertex Pharmaceuticals Incorporated (VRTX) stock rating?
As of today, Vertex Pharmaceuticals Incorporated has a stock rating of 6 (out of 10), which is considered Good.
is Vertex Pharmaceuticals Incorporated (VRTX) a good stock to buy?
As of today, Vertex Pharmaceuticals Incorporated has a Good stock rating, which is 61.6% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.